Elena Viboch
Direttore/Membro del Consiglio presso Pear Therapeutics (US), Inc.
Profilo
Elena Viboch is currently a Director at Pear Therapeutics (US), Inc., Deep Genomics, Inc., and Paradigm Health, Inc. She is also a Partner at General Catalyst LLC.
Previously, she worked as a Director at NanoString Technologies, Inc. and Carmot Therapeutics, Inc. She was also an Investment Director at SB Investment Advisers (UK) Ltd.
Ms. Viboch has a background in business and holds a graduate degree from The Johns Hopkins University, an undergraduate degree from Swarthmore College, and an MBA from Harvard Business School.
Posizioni attive di Elena Viboch
Società | Posizione | Inizio |
---|---|---|
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Direttore/Membro del Consiglio | - |
Deep Genomics, Inc.
Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Direttore/Membro del Consiglio | - |
General Catalyst LLC
General Catalyst LLC Investment ManagersFinance General Catalyst LLC (General Catalyst) is a venture capital firm founded in 2000 by Joel Cutler, David Fialkow, Bill Fitzgerald, David Orfao and John Simon. The firm is headquartered in Cambridge, Massachusetts. | Investitore di Private Equity | 01/01/2022 |
Paradigm Health, Inc.
Paradigm Health, Inc. Packaged SoftwareTechnology Services Paradigm Health, Inc. develops a platform for clinical research. The company is based in New York, NY and has subsidiaries in the United States. The company was founded by Milind Kamkolkar. Kent Thoelke has been the CEO of the company since 2023. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Elena Viboch
Società | Posizione | Fine |
---|---|---|
SB Investment Advisers (UK) Ltd.
SB Investment Advisers (UK) Ltd. Investment ManagersFinance SB Investment Advisers (UK) Ltd. is a Private Equity firm, a subsidiary of SoftBank Group Corp. founded in 2016 by Masayoshi Son. SB Investment Advisers (UK) Ltd. is headquartered in London, UK. | Investitore di Private Equity | 01/01/2022 |
NANOSTRING TECHNOLOGIES, INC. | Direttore/Membro del Consiglio | 01/01/2019 |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Direttore/Membro del Consiglio | 01/01/2017 |
RAPT THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2016 |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 01/07/2014 |
Formazione di Elena Viboch
Swarthmore College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
The Johns Hopkins University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
RAPT THERAPEUTICS, INC. | Health Technology |
NANOSTRING TECHNOLOGIES, INC. | Health Technology |
Aziende private | 9 |
---|---|
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | Finance |
Putnam Associates LLC
Putnam Associates LLC Miscellaneous Commercial ServicesCommercial Services Putnam Associates LLC engages in the provision of strategic consulting serving biopharmaceutical, diagnostics, and medical device clients. It specializes in corporate strategy, portfolio licensing and development strategy, new product, established products and franchise strategy, pricing, reimbursement and market access, and other related strategic projects. The company was founded by Kevin J. Gorman in 1988 and is headquartered in Boston, MA. | Commercial Services |
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Technology Services |
Deep Genomics, Inc.
Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Health Technology |
SB Investment Advisers (UK) Ltd.
SB Investment Advisers (UK) Ltd. Investment ManagersFinance SB Investment Advisers (UK) Ltd. is a Private Equity firm, a subsidiary of SoftBank Group Corp. founded in 2016 by Masayoshi Son. SB Investment Advisers (UK) Ltd. is headquartered in London, UK. | Finance |
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Health Technology |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
General Catalyst LLC
General Catalyst LLC Investment ManagersFinance General Catalyst LLC (General Catalyst) is a venture capital firm founded in 2000 by Joel Cutler, David Fialkow, Bill Fitzgerald, David Orfao and John Simon. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Paradigm Health, Inc.
Paradigm Health, Inc. Packaged SoftwareTechnology Services Paradigm Health, Inc. develops a platform for clinical research. The company is based in New York, NY and has subsidiaries in the United States. The company was founded by Milind Kamkolkar. Kent Thoelke has been the CEO of the company since 2023. | Technology Services |
- Borsa valori
- Insiders
- Elena Viboch